amgen inc (AMGN) Key Developments
Amgen Declares Dividend for the Second Quarter of 2014, Payable on June 6, 2014
Mar 5 14
Amgen announced that its Board of Directors declared a $0.61 per share dividend for the second quarter of 2014. The dividend will be paid on June 6, 2014, to all stockholders of record as of the close of business on May 15, 2014.
Omnicare Settles False Claims Act Allegations for $4.19 Million in Improper Marketing of Drug Used on Nursing Home Patients Lawsuit
Feb 27 14
Following on the heels of a $24.9 million settlement with Amgen last April, Omnicare has resolved allegations that it received remuneration from Amgen in order to influence the selection and utilization of the drug Aranesp throughout the nations' nursing homes. Aranesp, with limited indications, is used to treat anemia. The False Claims Act case, brought in U.S. District Court in South Carolina by whistleblower Frank Kurnik, alleged violations by Amgen, along with pharmacy providers Omnicare, PharMerica and Kindred. While the claims against Amgen and Omnicare have now been resolved, the case is proceeding against PharMerica and Kindred. The settlement reached between the U.S. Department of Justice, Kurnik, and Omnicare outlines the settled claims as follows: From the period between September 1, 2003 through June 30, 2005, the United States alleges that Omnicare solicited and received remuneration from Amgen Inc. in the form of purported discounts, purported market-share rebates, grants, honoraria, speaker fees, consulting services, dinners, travel or fees for the purchase of data, and that this remuneration was solicited and received in exchange for Omnicare's influencing of health care providers' selection and utilization of Aranesp within long-term care settings, and for implementing 'Therapeutic Interchange' programs (also known as 'switching' programs) intended to identify patients who were taking a competitor drug and to switch those patients to Aranesp. The United States alleges that as a result of the foregoing Covered Conduct, Omnicare knowingly caused false and/or fraudulent claims for Aranesp to be submitted to Medicare, Medicaid, and other federal health care programs.
Amgen Inc. Presents at RBC Capital Markets 2014 Global Healthcare Conference, Feb-26-2014 04:05 PM
Feb 12 14
Amgen Inc. Presents at RBC Capital Markets 2014 Global Healthcare Conference, Feb-26-2014 04:05 PM. Venue: New York Palace Hotel, New York, New York, United States. Speakers: Arvind Sood, Vice President of Investor Relations.
Dako and Amgen Expand Collaboration with Plan to Develop New Diagnostic Test
Feb 11 14
Dako announced a new project with Amgen to develop a molecular diagnostic test using Dako's IQFISH hybridization buffer. The cutting-edge IQFISH hybridization buffer reduces diagnostic test turnaround time from 17 hours to just 3.5 hours. It enables pathology labs-for the first time-to run DNA-based hybridization assays quickly, with distinct and higher fluorescent signal intensity compared to traditional FISH assays. This ability represents a major advance for pathologists, oncologists and ultimately patients. Companion diagnostics are becoming increasingly important in treating disease. They provide a way to both improve patient care and reduce health-care costs by matching specific therapies to the individuals most likely to benefit from them, since all patients do not respond in the same way.
Amgen Inc. Presents at 8th Annual BIO Europe Spring 2014, Mar-10-2014 through Mar-12-2014
Feb 9 14
Amgen Inc. Presents at 8th Annual BIO Europe Spring 2014, Mar-10-2014 through Mar-12-2014. Venue: OVAL Lingotto, Turin, Italy. Presentation Date & Speakers: Mar-10-2014, John O'Connor, Executive Director, Peter Sandor, VP, Global Marketing, TA Head Oncology.